225 related articles for article (PubMed ID: 9633851)
1. Biological therapy of ovarian cancer: current directions.
Bookman MA
Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
[TBL] [Abstract][Full Text] [Related]
2. The immunobiology and immunotherapy of ovarian cancer.
Bookman MA; Bast RC
Semin Oncol; 1991 Jun; 18(3):270-91. PubMed ID: 1710393
[TBL] [Abstract][Full Text] [Related]
3. Serotherapy of ovarian cancer.
Lidor Y; Bast RC
Nat Immun Cell Growth Regul; 1988; 7(4):193-215. PubMed ID: 3070370
[TBL] [Abstract][Full Text] [Related]
4. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody therapy of ovarian cancer.
Nicodemus CF; Berek JS
Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
[TBL] [Abstract][Full Text] [Related]
7. Biologic therapy in the management of refractory ovarian cancer.
Bookman MA
Gynecol Oncol; 1993 Oct; 51(1):113-26. PubMed ID: 8244165
[TBL] [Abstract][Full Text] [Related]
8. Biologic and immunologic therapy of ovarian cancer.
Bookman MA; Berek JS
Hematol Oncol Clin North Am; 1992 Aug; 6(4):941-65. PubMed ID: 1500395
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies.
Nicodemus CF; Schultes BC; Hamilton BL
Expert Rev Vaccines; 2002 Jun; 1(1):35-48. PubMed ID: 12908511
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody therapy of cancer.
Weiner LM
Semin Oncol; 1999 Oct; 26(5 Suppl 14):43-51. PubMed ID: 10561017
[TBL] [Abstract][Full Text] [Related]
11. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
12. [The prospect of biologic therapy in ovarian cancer].
Qian HN
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):386-8. PubMed ID: 8001411
[No Abstract] [Full Text] [Related]
13. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
14. Biologic therapy and immunotherapy for ovarian cancer.
Bookman MA
Curr Opin Oncol; 1991 Oct; 3(5):901-7. PubMed ID: 1751581
[TBL] [Abstract][Full Text] [Related]
15. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
16. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
18. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials of HER-2/neu-specific vaccines.
Murray JL; Przepiorka D; Ioannides CG
Semin Oncol; 2000 Dec; 27(6 Suppl 11):71-5; discussion 92-100. PubMed ID: 11236031
[TBL] [Abstract][Full Text] [Related]
20. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]